Table 2.
Clinical trials of FDA-approved targeted agents with rare lung cancers enrolled
| Target | FDA-approved therapy | Clinical trial (phase) | Comparator | Treatment line | Rare lung cancers enrolled (n) | ORR | mPFS (mo) | mOS (mo) |
|---|---|---|---|---|---|---|---|---|
| EGFR | Osimertinib | FLAURA (III)31 | Erlotinib or Gefitinib | First-line | LASC (3), LCCa (5) | 80% | 18.9 | 38.6 |
| Mobocertinib | NCT02716116 (I/II)32 | No | Second-line | LCCa (1) | 28% | 7.3 | 24.0 | |
| MET | Capmatinib | GEOMETRY mono-1 (II)33 | No | Beyond first-line | LCCa (1) | 44% (68%)b | 5.4 | NA |
| Tepotinib | VISION (II)34 | No | First-line and beyond | PSC (1) | 46% | 8.5 | 17.1 | |
| KRAS | Sotorasib | CodeBreaK 100 (I)35 | No | Beyond first-line | LCCa (3) | 32% | 6.3 | 12.5 |
| BRAF | Dabrafenib plus Trametinib | BRF113928 (II)36 | No | First-line | LASC (1), LCCa (1) | 64% | 10.8 | 17.3 |
mOS, median overall survival; mPFS, median progression-free survival; ORR, objective response rate.
a
Not able to confirm exact histological subtypes due to the changing definition of LCC.
b
Indicates data for treatment on naive patients.